Gyre Therapeutics, Inc.
GYRE
$8.11
$0.354.51%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 4.17M | 7.25M | 12.09M | -88.82M | -85.97M |
| Total Depreciation and Amortization | 2.10M | 1.69M | 1.57M | 1.41M | 1.15M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 6.28M | 5.84M | 5.56M | 98.21M | 100.39M |
| Change in Net Operating Assets | -11.61M | -21.44M | -22.86M | -8.31M | -7.24M |
| Cash from Operations | 927.00K | -6.65M | -3.64M | 2.48M | 8.33M |
| Capital Expenditure | -1.01M | -2.21M | -2.32M | -4.70M | -5.99M |
| Sale of Property, Plant, and Equipment | 152.00K | 352.00K | 401.00K | 430.00K | 798.00K |
| Cash Acquisitions | -- | -- | -- | 5.46M | 5.46M |
| Divestitures | -- | -- | -- | -566.00K | -566.00K |
| Other Investing Activities | -4.61M | -8.84M | -17.97M | -17.16M | -19.26M |
| Cash from Investing | -5.47M | -10.70M | -19.88M | -16.54M | -19.55M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 27.20M | 3.45M | 2.64M | 1.31M | 933.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | 2.50M | 2.50M |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -2.22M | -657.00K | -536.00K | -169.00K | -119.00K |
| Cash from Financing | 24.98M | 2.79M | 2.10M | 3.64M | 3.31M |
| Foreign Exchange rate Adjustments | -50.00K | -177.00K | -273.00K | 213.00K | 278.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 20.39M | -14.74M | -21.70M | -10.21M | -7.63M |